Abstract:
:Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60% to 70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and preexisting cardiac disease may prevent the use of doxorubicin. Age greater than 65 years is a significant risk factor for anthracycline-induced cardiotoxicity, and therefore, the use of R-CHOP is often withheld from elderly patients. The feasibility of replacing doxorubicin with either epirubicin or etoposide in patients who have risk factors for heart complications is analyzed here. Clinical data of 223 DLBCL patients were retrospectively collected from hospital records. Fifty-five patients were treated with R-CHOP, 105 with R-CIOP (epirubicin instead of doxorubicin), 17 with R-CEOP (etoposide instead of doxorubicin), and 31 with R-CHOEP. Matched-pair analysis was carried out between 30 patients treated with R-CEOP and R-CHOP. For all patients, the 2-year progression-free survival (PFS) was 73.6%. In patients treated with R-CHOP, the 2-year PFS was 84.2%, with R-CIOP 64.4%, with R-CEOP 87.7%, and with R-CHOEP 83.2%. In matched-pair analysis, the 2-year PFS was 92.3% with R-CHOP and 86.2% with R-CEOP. The 2-year disease specific survival was 100% with R-CHOP and 86.2% with R-CEOP. In conclusion, R-CEOP offers reasonable PFS and disease specific survival in the treatment of DLBCL and good disease control can be achieved in elderly patients. Elderly patients with impaired cardiac function could benefit from the use of R-CEOP instead of R-CHOP. The results with R-CIOP were unsatisfactory, and we do not recommend using this protocol in elderly patients with cardiac disease.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Prusila REI,Peroja P,Jantunen E,Turpeenniemi-Hujanen T,Kuittinen Odoi
10.1002/hon.2572subject
Has Abstractpub_date
2019-04-01 00:00:00pages
136-142issue
2eissn
0278-0232issn
1099-1069journal_volume
37pub_type
杂志文章abstract::One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate. ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080103
更新日期:1990-01-01 00:00:00
abstract::Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...
journal_title:Hematological oncology
pub_type: 杂志文章,随机对照试验
doi:10.1002/hon.2141
更新日期:2015-06-01 00:00:00
abstract::During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.822
更新日期:2007-09-01 00:00:00
abstract::Mucosa-associated lymphatic tissue (MALT) lymphoma of the breast is an extremely rare disease; its pathogenesis is not clear because of the rarity of disease, and the best diagnostic method has yet to be established. The metabolic behavior of this lymphoma is not still clear because only a few case reports are present...
journal_title:Hematological oncology
pub_type:
doi:10.1002/hon.2376
更新日期:2017-12-01 00:00:00
abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2378
更新日期:2017-12-01 00:00:00
abstract::ABCG2 (BCRP) is a member of the ATP-binding cassette (ABC) family of cell surface transport proteins. ABCG2 expression occurs in a variety of normal tissues, and is relatively limited to primitive stem cells. ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux. The substrate ...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.714
更新日期:2003-09-01 00:00:00
abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析,评审
doi:10.1002/hon.2152
更新日期:2015-09-01 00:00:00
abstract::Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2195
更新日期:2016-09-01 00:00:00
abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900120104
更新日期:1994-01-01 00:00:00
abstract::Ten patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER-treatment or of the RA-treatment on a...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070407
更新日期:1989-07-01 00:00:00
abstract::Multiple myeloma, which is a monoclonal plasma cell malignancy, still remains incurable despite recent progress in our understanding of this disorder. Adoptive immunotherapy of multiple myeloma using cytokine-induced killer cells is yielding promising results in clinical trials; however, some myeloma cells still evade...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2326
更新日期:2017-12-01 00:00:00
abstract::High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Trea...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2014
更新日期:2013-03-01 00:00:00
abstract::The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/(sici)1099-1069(199711)15:4<191::aid-hon61
更新日期:1997-11-01 00:00:00
abstract::We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.733
更新日期:2004-09-01 00:00:00
abstract::We verified whether early resistance to treatment can be predicted in a subset of patients with very favourable, early stage Hodgkin lymphoma, treated with VBM (vinblastine, bleomycin and methotrexate) chemotherapy and involved-field radiotherapy, an effective combination with very low early and late toxicity. The rel...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2035
更新日期:2013-09-01 00:00:00
abstract::Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2647
更新日期:2019-10-01 00:00:00
abstract::The goal of current management of patients with chronic phase chronic myeloid leukemia (CML) is to reach treatment-free remission with sustained deep molecular remission (DMR) being the prerequisite therefor. Second-generation tyrosine kinase inhibitors can induce deeper and faster remission than imatinib, but are oft...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2786
更新日期:2020-12-01 00:00:00
abstract::Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2092
更新日期:2014-06-01 00:00:00
abstract::We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 84 induction but rel...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1002/hon.2900090411
更新日期:1991-07-01 00:00:00
abstract::Bone marrow (BM) trephine biopsy is a part of routine staging of patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The significance of lymphoid monoclonal population on flow cytometry (FC) of the BM aspirate in the presence of negative BM histology has not been clarified. In this study, we assessed ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2127
更新日期:2015-03-01 00:00:00
abstract::We compare 30 biopsies each of Pattern 1 angioimmunoblastic T-cell lymphoma (AITL1) and reactive lymphoid hyperplasia (RLH) by immunohistology, in-situ hybridization for Epstein-Barr virus-encoded RNA and T-cell receptor-γ (TRG)-clonality. AITL1 cases, more often than RLH controls, were older [median ages 61 (range 23...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2116
更新日期:2014-09-01 00:00:00
abstract::In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/(sici)1099-1069(199912)17:4<149::aid-hon64
更新日期:1999-12-01 00:00:00
abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2724
更新日期:2020-10-01 00:00:00
abstract::Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2344
更新日期:2017-12-01 00:00:00
abstract::Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析
doi:10.1002/hon.2173
更新日期:2015-12-01 00:00:00
abstract::Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2493
更新日期:2018-04-01 00:00:00
abstract::Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2729
更新日期:2020-08-01 00:00:00
abstract::Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080205
更新日期:1990-03-01 00:00:00
abstract::Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patients with initial le...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900030107
更新日期:1985-01-01 00:00:00
abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2775
更新日期:2020-10-01 00:00:00